FDA Adverse Event Injury Summary report: N

EDWARDS SAPIEN TRANSCATHETER HEART VALVE

MDR report key: 3851158 · Received June 5, 2014

Report

Report Number
2015691-2014-01303
Event Type
Injury
Date Received
June 5, 2014
Date of Event
May 13, 2014
Report Date
May 13, 2014
Manufacturer
EDWARDS LIFESCIENCES
Product Code
NPT
PMA / PMN Number
P110021
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
IL, US
Reporter Occupation
PHYSICIAN

Narratives

Additional Manufacturer Narrative · 1

PER THE INSTRUCTIONS FOR USE, CONDUCTION SYSTEM INJURIES (HEART BLOCK) WHICH MAY REQUIRE A PERMANENT PACEMAKER ARE POTENTIAL ADVERSE EVENTS ASSOCIATED WITH BALLOON AORTIC VALVULOPLASTY, DEPLOYMENT OF THE PROSTHETIC VALVE, AND THE OVERALL TAVR PROCEDURE. ACCORDING TO THE VALVE ACADEMIC RESEARCH CONSORTIUM (VARC) GUIDELINES, THE CLOSE ANATOMICAL RELATIONSHIP BETWEEN THE AORTIC VALVE COMPLEX AND THE BRANCHING ATRIOVENTRICULAR BUNDLE MAY PROVIDE AN EXPLANATION FOR THESE COMPLICATIONS OF THE TAVR PROCEDURE. ACCORDING TO LITERATURE REVIEW, AND AS DOCUMENTED IN A CLINICAL TECHNICAL SUMMARY WRITTEN BY EDWARDS LIFESCIENCES, ATRIOVENTRICULAR CONDUCTION DISTURBANCES AFTER TAVR ARE ASSOCIATED WITH MANY PATIENT RELATED AND PROCEDURAL RELATED FACTORS, INCLUDING PRE-OPERATIVE CO-MORBID STATUS, THE DEGREE AND BULKINESS OF AORTIC VALVE AND ANNULAR CALCIFICATION, INTER-VENTRICULAR SEPTAL THICKNESS, PRE-EXISTING ELECTROCARDIOGRAM ABNORMALITIES, THE DEPTH OF PROSTHESIS IMPLANTATION, AND THE PROFILE OF THE IMPLANTED PROSTHESIS. UNLIKE CONVENTIONAL AVR, WHERE THERE MAY BE LOCALIZED TRAUMA DUE TO DECALCIFICATION OF THE ANNULUS AND/OR SUTURE PLACEMENT IN THE PROXIMITY OF THE AV NODE OR THE BUNDLES, TAVR MAY CAUSE CONDUCTION ABNORMALITIES THROUGH MECHANICAL IMPINGEMENT OF THE CONDUCTION SYSTEM BY THE PROSTHESIS. THE MECHANISMS OF THE DEVELOPMENT OF HEART BLOCK AFTER TAVR ARE WELL DOCUMENTED AND DESCRIBED IN THE LITERATURE. IT IS ALSO DOCUMENTED THAT PRE-EXISTING HEART BLOCK IS COMMON IN PATIENTS UNDERGOING TAVR OR SURGICAL AVR AND ANOTHER 4-6 % WILL DEVELOP POSTOPERATIVE HEART BLOCK, POTENTIALLY REQUIRING A PERMANENT PACEMAKER. IN THIS CASE, PROCEDURAL FACTORS (PRESSURE FROM THE IMPLANTED VALVE ON THE CARDIAC STRUCTURES) LIKELY CONTRIBUTED TO THIS EVENT. THE IFU AND TRAINING MANUALS HAVE BEEN REVIEWED AND NO INADEQUACIES HAVE BEEN IDENTIFIED WITH REGARDS TO WARNINGS, CONTRAINDICATIONS, AND THE DIRECTIONS/CONDITIONS FOR THE SUCCESSFUL USE OF THE DEVICE. COMPLAINT HISTORIES FOR ALL REPORTED EVENTS ARE REVIEWED AGAINST TRENDING CONTROL LIMITS ON A MONTHLY BASIS, AND ANY EXCURSIONS ABOVE THE CONTROL LIMITS ARE ASSESSED AND DOCUMENTED AS PART OF THIS MONTHLY REVIEW. NO CORRECTIVE OR PREVENTATIVE ACTIONS ARE REQUIRED AT THIS TIME.

Description of Event or Problem · 1

DURING THE TRANSAPICAL TAVR, A 26MM SAPIEN VALVE WAS DEPLOYED WITH A FINAL POSITION OF 70:30 AORTIC/VENTRICULAR. THE PATIENT DEVELOPED COMPLETE HEART BLOCK POST DEPLOYMENT OF THE VALVE. POST PROCEDURE, THE TEMPORARY PACEMAKER WAS LEFT IN PLACE AND THE PATIENT WAS TRANSFERRED TO RECOVERY IN STABLE CONDITION. THE PATIENT RECEIVED A PERMANENT PACEMAKER 2 DAYS POST TAVR. THE PATIENT¿S NATIVE ANNULUS DIAMETER MEASURED 18.5 X 28.2MM WITH MODERATE NATIVE VALVE AND ROOT CALCIFICATION NOTED. THE COAXIAL ALIGNMENT OF THE DELIVERY SYSTEM/ VALVE AND THE IMAGE INTENSIFIER ANGLE WERE REPORTED TO BE GOOD. PER THE DISCUSSION WITH THE PHYSICIAN, PRESSURE FROM THE IMPLANTED VALVE ON THE LVOT LIKELY CAUSED THE COMPLETE HEART BLOCK.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
329660 EDWARDS SAPIEN TRANSCATHETER HEART VALVE AORTIC VALVE, PROSTHESIS, PERCUTANEOUSLY DELIVERED NPT EDWARDS LIFESCIENCES 9000TFX26A

Patients

Seq Age Sex Outcome Treatment
1 85 YR Required Intervention